DPP4 in diabetes
D Röhrborn, N Wronkowitz, J Eckel - Frontiers in immunology, 2015 - frontiersin.org
Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
RA DeFronzo, JA Davidson… - Diabetes, Obesity and …, 2012 - Wiley Online Library
The maintenance of normal glucose homeostasis requires a complex, highly integrated
interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system …
interaction among the liver, muscle, adipocytes, pancreas and neuroendocrine system …
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall, MC Riddle, J Rosenstock… - Diabetes …, 2005 - Am Diabetes Assoc
OBJECTIVE—This study evaluated the effects of exenatide, a novel incretin mimetic, in
hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with …
hyperglycemic patients with type 2 diabetes unable to achieve glycemic control with …
Glucose metabolism and regulation: beyond insulin and glucagon
SL Aronoff, K Berkowitz, B Shreiner… - Diabetes spectrum, 2004 - Am Diabetes Assoc
Insulin and glucagon are potent regulators of glucose metabolism. For decades, we have
viewed diabetes from a bi-hormonal perspective of glucose regulation. This perspective is …
viewed diabetes from a bi-hormonal perspective of glucose regulation. This perspective is …
[HTML][HTML] A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
L Prasad-Reddy, D Isaacs - Drugs in context, 2015 - ncbi.nlm.nih.gov
The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 …
DJ Augeri, JA Robl, DA Betebenner… - Journal of medicinal …, 2005 - ACS Publications
Efforts to further elucidate structure− activity relationships (SAR) within our previously
disclosed series of β-quaternary amino acid linked l-cis-4, 5-methanoprolinenitrile dipeptidyl …
disclosed series of β-quaternary amino acid linked l-cis-4, 5-methanoprolinenitrile dipeptidyl …
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial
RJ Heine, LF Van Gaal, D Johns, MJ Mihm… - Annals of internal …, 2005 - acpjournals.org
Background: Physicians may use either insulin or exenatide injections for patients with type
2 diabetes mellitus who have poor glycemic control despite taking oral blood glucose …
2 diabetes mellitus who have poor glycemic control despite taking oral blood glucose …
β-cell failure in diabetes and preservation by clinical treatment
BL Wajchenberg - Endocrine reviews, 2007 - academic.oup.com
There is a progressive deterioration in β-cell function and mass in type 2 diabetics. It was
found that islet function was about 50% of normal at the time of diagnosis, and a reduction in …
found that islet function was about 50% of normal at the time of diagnosis, and a reduction in …
[HTML][HTML] Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain
Alzheimer disease (AD) is the most common form of dementia among the elderly and is
characterized by progressive loss of memory and cognition. Epidemiological data show that …
characterized by progressive loss of memory and cognition. Epidemiological data show that …
Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that includes obesity,
diabetes, and dyslipidemia. Accumulating evidence implies that MetS contributes to the …
diabetes, and dyslipidemia. Accumulating evidence implies that MetS contributes to the …